SLU-PP-332: mechanism of action

SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), a class of orphan nuclear receptors. It is described in the literature as a pan-ERR agonist and an exercise mimetic, and it is widely used as a chemical probe for ERR activation [2]. The evidence block for this page does not provide a sequence, molecular formula, or molecular weight for SLU-PP-332; those identifiers are not reported here. The work on this compound centres on the ERR nuclear receptor family and its downstream control of mitochondrial metabolism and exercise-responsive transcription [2].

ERRs are described as master regulators of mitochondrial metabolism and exercise-responsive transcription, and they regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the Krebs cycle [2][6]. Because only a limited number of synthetic ERR agonists with suitable potency and drug-like properties have been reported, SLU-PP-332 has served as a scaffold for structure-activity relationship work and for the development of related compounds such as SLU-PP-915 [2][1].

Research Studies

SLU-PP-332 and ERR activation in cell-based functional assays

The first comprehensive structure-activity relationship (SAR) analysis of the SLU-PP-332 scaffold integrated chemical synthesis, cell-based functional assays, downstream gene-expression profiling, and additional characterization [2]. That work was undertaken because the structural features governing the potency, efficacy, selectivity, and drug-like properties of SLU-PP-332 had not been systematically elucidated, despite its status as a well-established exercise mimetic and widely used ERR probe [2]. The SAR analysis is the source for the claim that the scaffold can be optimized toward improved ERR signalling properties [2].

SLU-PP-332 and in vitro metabolism in human liver S9 fractions

SLU-PP-332 and SLU-PP-915 were characterized using liquid chromatography-high resolution (tandem) mass spectrometry (LC-HRMS/MS), and the in vitro metabolic transformation products of both compounds were prepared using human liver S9 fractions [1]. The stated rationale for that work was that ERR agonists such as SLU-PP-332 and SLU-PP-915 are being investigated as exercise mimetics because of their ability to trigger human physiological processes similar to those initiated by physical activity, which prompted consideration of these compounds as drugs potentially relevant to sports drug testing programmes [1].

SLU-PP-332 and metabolite identification for doping-control purposes

A separate analysis identified in vitro metabolites of SLU-PP-332, described as an ERRα/β/γ agonist, for doping-control purposes [4]. That report notes that exercise mimetics mimic physical activity and are considered relevant to the prevention and progression of chronic metabolic diseases including obesity and Type 2 diabetes, and that the World Anti-Doping Agency prohibits the use of exercise mimetics and metabolic modulators in sports [4].

SLU-PP-332 and ERR targeting in myoblasts from inactive women

A pilot study evaluated ERR targeting in myoblasts isolated from the skeletal muscle of inactive women, assessing metabolic and expression changes associated with ERR activation [3]. Twenty women undergoing hip arthroplasty for coxarthrosis were enrolled and divided into an active group (n = 10) and an inactive group (n = 10) based on self-reported physical activity [3]. The introduction to that study states that ERRs have been suggested as a potential therapeutic target to counteract muscle decline associated with aging or inactivity, and that ERRs are known to regulate mitochondrial function and cellular respiration by up-regulating key factors in muscle responses to exercise [3]. This is a human myoblast model; it is not a clinical trial of SLU-PP-332 in humans.

SLU-PP-332 and metabolic syndrome in animal models

A synthetic ERR agonist has been reported to alleviate metabolic syndrome in animal work [7]. That report frames pharmacological exercise mimetics as potentially effective in the treatment of a range of diseases including obesity and metabolic syndrome, and describes the prior development of SLU-PP-332 as an ERR agonist [7]. The finding is animal-only; no human efficacy data are provided in the evidence block.

SLU-PP-915 and aerobic exercise capacity in animal models

SLU-PP-915, an orally active ERR agonist related to the SLU-PP-332 scaffold, has been reported to enhance aerobic exercise capacity [6]. That report describes ERRα, ERRβ, and ERRγ as orphan nuclear receptors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the Krebs cycle, and states that ERRs are essential for skeletal muscle adaptation to aerobic exercise and represent promising targets [6]. This finding is animal-only.

ERRα/β/γ activation as an exercise mimetic: review-level evidence

A systematic review examined the physiological, molecular, and clinical evidence on activation of the orphan nuclear receptors ERRα/β/γ as a molecular strategy to mimic exercise-induced benefits, in the context of physical inactivity contributing to the development of chronic diseases [5]. That review is a synthesis of existing evidence rather than a primary experimental study [5].

Comparison of evidence types across the SLU-PP-332 literature

SLU-PP-332 and the limits of the current evidence

The evidence block for this page does not contain human dosing data, human clinical outcomes, or pharmacokinetic parameters for SLU-PP-332. The human-derived material described is limited to in vitro systems: human liver S9 fractions for metabolism [1] and myoblasts isolated from skeletal muscle of inactive women for ERR activation readouts [3]. Findings on metabolic syndrome and aerobic exercise capacity come from animal models [7][6]. Any statement about what SLU-PP-332 does in a living human body is therefore outside what this evidence supports.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. https://europepmc.org/article/PMC/PMC12835572
• [2] Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. https://europepmc.org/article/PMC/PMC13112601
• [3] Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. https://europepmc.org/article/PMC/PMC12277287
• [4] Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. https://pubmed.ncbi.nlm.nih.gov/41688415/
• [5] [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]. https://pubmed.ncbi.nlm.nih.gov/42024694/
• [6] An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. https://pubmed.ncbi.nlm.nih.gov/41421047/
• [7] A Synthetic ERR Agonist Alleviates Metabolic Syndrome. https://europepmc.org/article/PMC/PMC10801787